Cancer News and Research

Latest Cancer News and Research

Aggressive prostate cancer patients tend to retain denser bones

Men who develop prostate cancer, especially the more aggressive and dangerous forms that spread throughout the body, tend to retain denser bones as they age than men who stay free of the disease, suggests new research from Johns Hopkins and the National Institute on Aging (NIA), part of the National Institutes of Health.

29 Jul 2010

AMAG attributes increased second-quarter revenues of $18.8 million to Feraheme

AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the second quarter and six months ended June 30, 2010. For the second quarter, AMAG reported total revenue of $18.8 million, including $16.0 million of Feraheme® (ferumoxytol) Injection for intravenous (IV) use net product revenues.

29 Jul 2010

HemoBioTech receives patent for HemoTech treatment of acute blood loss

HemoBioTech announced today the issuance of a new patent US 7,759,306 B2, Methods of Treating Acute Blood Loss. HemoBioTech has an exclusive worldwide license from Texas Tech University to commercialize the technology. The new patent continues to May 16, 2026. The major advance in HemoTech is the presence of Adenosine which has anti-inflammatory activity.

29 Jul 2010

Intercept signs CRADA with NIDDK for study of obeticholic acid in nonalcoholic steatohepatitis

Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for chronic fibrotic and metabolic diseases, today announced the signing of a cooperative research and development agreement (CRADA) with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health to conduct a double blind, multi-center, study to evaluate the effects of obeticholic acid in patients with nonalcoholic steatohepatitis (NASH).

28 Jul 2010

Pain Therapeutics second-quarter collaboration revenue decreases to $0.1 million

Pain Therapeutics, Inc., a biopharmaceutical company, today reported second quarter financial results. Net loss for the quarter ended June 30, 2010 was $0.8 million, or $0.02 per share, compared to net loss of $34,000, or $0.00 per share, for the second quarter of 2009. Pain Therapeutics had cash, cash equivalents and marketable securities of $176.2 million, or about $4.14 cash per share, and no debt as of June 30, 2010.

28 Jul 2010

Kyowa Hakko Kirin initiates Phase 2 trial of ARQ 197 for gastric cancer: ArQule

ArQule, Inc. today announced the initiation of a Phase 2, single agent trial with ARQ 197 in gastric cancer by Kyowa Hakko Kirin, its exclusive licensee for the development and commercialization of ARQ 197 in the Asian territory consisting of Japan, China (including Hong Kong), South Korea and Taiwan. Initiation of this trial will trigger a $5 million milestone payment to ArQule from Kyowa Hakko Kirin.

28 Jul 2010

Exact Sciences reports total revenues of $1.3M for second-quarter 2010

Exact Sciences Corp. today announced its financial results for the second quarter ended June 30, 2010.

28 Jul 2010

Researchers establish new criteria for liver transplantation

Researchers at the University of California, San Francisco propose that treatments used on liver cancers beyond the established Milan criteria for liver transplantation may be appropriate for all patients with hepatocellular carcinoma who are listed for transplantation. Full details appear in the August issue of Liver Transplantation, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

28 Jul 2010

Allos reports topline results from Phase 2b trial of FOLOTYN vs erlotinib in advanced NSCLC

Allos Therapeutics, Inc. today announced topline results from the Company's randomized Phase 2b investigational trial of FOLOTYN® (pralatrexate injection) versus erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC) who had received one or two prior systemic treatments including at least one prior platinum-based regimen. The objective of the trial was to estimate the efficacy of FOLOTYN compared to that of erlotinib as assessed by overall survival.

28 Jul 2010

Allos reports net loss of $20.0 million for second-quarter 2010

Allos Therapeutics, Inc. today reported its financial results and business highlights for the quarter and six months ended June 30, 2010.

28 Jul 2010

Vitro Diagnostics, Mokshagundam Biotechnologies enter contract to develop stem cell-derived food

Vitro Diagnostics, Inc., dba Vitro Biopharma, announced that it has entered into a contract with Mokshagundam Biotechnologies, a private research organization established to develop alternative meat sources, to develop cell culture medium for use in exploration of alternative food sources derived from stem cells.

28 Jul 2010

New book introduces practical information on how to find job opportunities

For those with an aptitude in science and an interest in working with medical discovery teams, careers at drug, medical device, and contract research organization companies can be fulfilling. A new book from Cold Spring Harbor Laboratory Press, Career Opportunities in Clinical Drug Research, introduces readers to entry-level clinical job opportunities and explains how to qualify for them.

28 Jul 2010

Price of sun overindulgence and tanning misuse is not just skin deep

It's what marketers lead us to believe is the picture of glowing health - the ultimate tan. But sun overindulgence and tanning misuse does have a price. And it's not just skin deep.

28 Jul 2010

Aphios awarded US patent for compositions, methods for treating diseases involving 5-α reductase enzyme

Aphios® Corporation today announced that it was awarded United States Patent No. 7,744,935 B2 for "Compositions and Methods for Inhibiting 5-α Reductase," granted June 29, 2010. This invention is related to compositions and methods for treating diseases involving the 5-alpha (α) reductase enzyme.

28 Jul 2010

New £50M fund made available to help patients get access to innovative new cancer drugs

The government has announced a new £50 million fund to improve access to cancer drugs until the new Cancer Drugs Fund comes into effect in April 2011.

28 Jul 2010

Positive results from study with Genome Sequencer FLX System for HIV drug-resistant mutation detection

454 Life Sciences, a Roche Company, has announced promising new results from a multi-site collaborative research study which used the company's Genome Sequencer FLX System to perform HIV drug-resistant mutation detection.

28 Jul 2010

Roche to present diagnostics testing solutions at 2010 Clinical Lab Expo

Roche is featuring a diverse portfolio of diagnostics testing solutions for healthcare professionals in booth #2808 at the AACC/CSCC 2010 Clinical Lab Expo here, July 27-29 – and it's giving them a unique way to see firsthand where their own "dream lab" might take them.

From Roche Sequencing and Life Science 28 Jul 2010

Astellas extends non-exclusive license agreement with Regeneron for VelocImmune technology

Regeneron Pharmaceuticals, Inc. and Astellas Pharma Inc. announced that Astellas has extended through 2023 the non-exclusive license agreement that allows Astellas to utilize Regeneron's VelocImmune® technology in its internal research programs to discover fully human monoclonal antibody product candidates.

28 Jul 2010

Research on impact of BCL2 markers on breast cancer tumours

A new predictive marker which could help doctors to decide whether breast cancer patients would benefit from chemotherapy has been identified by a team of scientists.The study, part-funded by Cancer Research UK and published in the British Journal of Cancer today (Wednesday), shows for the first time how this molecular marker has been singled out as an independent factor in examining a breast cancer patient's tumour.

28 Jul 2010

NICE publishes new guideline to help improve care, treatment for patients with CUP

The National Institute for Health and Clinical Excellence has published a new guideline which should help to improve care for thousands of patients with advanced cancer that has spread from an unknown primary location.

28 Jul 2010

Cancer News and Research

Latest Cancer News and Research

Aggressive prostate cancer patients tend to retain denser bones

AMAG attributes increased second-quarter revenues of $18.8 million to Feraheme

HemoBioTech receives patent for HemoTech treatment of acute blood loss

Intercept signs CRADA with NIDDK for study of obeticholic acid in nonalcoholic steatohepatitis

Pain Therapeutics second-quarter collaboration revenue decreases to $0.1 million

Kyowa Hakko Kirin initiates Phase 2 trial of ARQ 197 for gastric cancer: ArQule

Exact Sciences reports total revenues of $1.3M for second-quarter 2010

Researchers establish new criteria for liver transplantation

Allos reports topline results from Phase 2b trial of FOLOTYN vs erlotinib in advanced NSCLC

Allos reports net loss of $20.0 million for second-quarter 2010

Vitro Diagnostics, Mokshagundam Biotechnologies enter contract to develop stem cell-derived food

New book introduces practical information on how to find job opportunities

Price of sun overindulgence and tanning misuse is not just skin deep

Aphios awarded US patent for compositions, methods for treating diseases involving 5-α reductase enzyme

New £50M fund made available to help patients get access to innovative new cancer drugs

Positive results from study with Genome Sequencer FLX System for HIV drug-resistant mutation detection

Roche to present diagnostics testing solutions at 2010 Clinical Lab Expo

Astellas extends non-exclusive license agreement with Regeneron for VelocImmune technology

Research on impact of BCL2 markers on breast cancer tumours

NICE publishes new guideline to help improve care, treatment for patients with CUP

Industry Focus eBook - Oncology (1st Edition) eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in